It seems that reimbursement extensions for severe atopic dermatitis treatments like Dupxient to benefit pediatric and adolescent patients will only be possible after next year.

This is because the current reimbursement review process in progress would render reimbursements within the year difficult.

This news was revealed in the written QA response released by the Health Insurance Review and Assessment Service on the 13th after the NA audit.

HIRA disclosed the reimbursement review progress of the treatments in response to the claim made by Rep. Young-Seok Suh of the Democratic Party of Korea on how the government should hasten reimbursement of severe atopic dermatitis tre